# Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction

> **NCT06059066** · NA · COMPLETED · sponsor: **The Methodist Hospital Research Institute** · enrollment: 78 (actual)

## Conditions studied

- Neurogenic Bladder
- Lower Urinary Tract Symptoms
- Overactive Bladder
- Neuro: Neurogenic Bladder
- Neurogenic Detrusor Overactivity

## Interventions

- **PROCEDURE:** Standard number of injection sites
- **PROCEDURE:** Reduced number of injection sites

## Key facts

- **NCT ID:** NCT06059066
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-04
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2025-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06059066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06059066, "Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06059066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*